Pancreatic Cancer Research

ResearcherSanofi (France)Active in the last 2 years

Marianne Sinn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7155-1278; OpenAlex author ID A5103037024, A5109899009, A5110935184. Sources: OpenAlex.

Their work

Papers
47 (first author 8, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
110
Papers, trials and grants by year

2013: 5 papers · 2014: 7 papers · 2015: 4 papers · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 8 papers · 2023: 3 papers · 2024: 1 paper · 2025: 4 papers · 2026: 1 paper

Papers 47

  1. Concordance between GPT-4 and a multidisciplinary tumor board in pancreatic cancer: A prospective pilot study. Co-author DOI 10.1007/s00423-026-04242-9↗
  2. Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35443↗
  3. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  4. Pancreatic Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2024 in Barcelona. First author DOI 10.1159/000547154↗
  5. Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03262-x↗
  6. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. First author DOI 10.1002/2056-4538.12377↗
  7. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  8. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/clinchem/hvac214↗
  9. Effects of Exercise Training on Patient-Specific Outcomes in Pancreatic Cancer Patients: A Scoping Review. First author DOI 10.3390/cancers15245899↗
  10. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  11. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  12. Multimodal survival prediction in advanced pancreatic cancer using machine learning. Co-author DOI 10.1016/j.esmoop.2022.100555↗
  13. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  14. Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications. Co-author DOI 10.3389/fcell.2022.918795↗
  15. Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines10112955↗
  16. Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers14184405↗
  17. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Co-author DOI 10.3390/jcm11164905↗
  18. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. Co-author DOI 10.1016/j.ebiom.2021.103327↗
  19. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Last author DOI 10.1016/j.ejca.2021.03.036↗
  20. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  21. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic can… Co-author DOI 10.1016/j.ejca.2020.06.032↗
  22. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
  23. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospecti… Co-author DOI 10.1016/j.ejca.2018.06.001↗
  24. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41416-018-0093-y↗
  25. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejca.2017.06.016↗
  26. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  27. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. Co-author DOI 10.1371/journal.pone.0186341↗
  28. Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patien… Co-author DOI 10.21873/anticanres.11952↗
  29. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. First author DOI 10.1016/j.prp.2016.06.001↗
  30. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. Co-author DOI 10.1097/mpa.0000000000000533↗
  31. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. Co-author DOI 10.4251/wjgo.v8.i3.248↗
  32. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Last author DOI 10.1002/jso.23951↗
  33. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Co-author DOI 10.1016/j.ejca.2015.05.005↗
  34. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000365↗
  35. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. Co-author DOI 10.1200/jco.2014.55.1481↗
  36. [Multimodal treatment of pancreatic cancer]. First author DOI 10.1007/s00108-013-3316-6↗
  37. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Co-author DOI 10.1038/bjc.2014.495↗
  38. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Co-author DOI 10.1093/annonc/mdu084↗
  39. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000077↗
  40. Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy. Co-author DOI 10.1155/2014/452089↗
  41. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. Co-author DOI 10.1186/1471-2407-14-204↗
  42. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from … Co-author DOI 10.1200/jco.2013.53.6995↗
  43. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Co-author DOI 10.1001/jama.2013.279201↗
  44. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. Co-author DOI 10.1002/jso.23409↗
  45. [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. First author DOI 10.1055/s-0033-1349608↗
  46. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Co-author DOI 10.3389/fonc.2013.00155↗
  47. Blood group determinates incidence for pancreatic cancer in Germany. Co-author DOI 10.3389/fphys.2013.00118↗

Closest collaborators

The 25 strongest of 110 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Uwe Pelzer · 30 shared papers, 2013–2024 · strength 2.08
  2. Hanno B. Riess · 31 shared papers, 2013–2024 · strength 2.04
  3. Faik Güntac Uzunoglu · 10 shared papers, 2022–2026 · strength 1.77
  4. Marcus Bahra · 23 shared papers, 2013–2022 · strength 1.41
  5. Helmut Oettle · 19 shared papers, 2013–2024 · strength 1.41
  6. Jana Käthe Striefler · 20 shared papers, 2013–2022 · strength 1.41
  7. Jakob Robert Izbicki · 7 shared papers, 2022–2025 · strength 1.10
  8. Harriet Wikman · 6 shared papers, 2022–2025 · strength 0.99
  9. Christine Nitschke · 6 shared papers, 2022–2025 · strength 0.99
  10. Jens Stieler · 15 shared papers, 2013–2022 · strength 0.76
  11. Jens Thomas Siveke · 6 shared papers, 2022–2025 · strength 0.74
  12. Thilo Hackert · 3 shared papers, 2025–2026 · strength 0.67
  13. Philipp Lohneis · 9 shared papers, 2014–2021 · strength 0.61
  14. Bruno Valentin Sinn · 10 shared papers, 2013–2021 · strength 0.58
  15. Carsten Denkert · 10 shared papers, 2013–2021 · strength 0.58
  16. Julian Götze · 3 shared papers, 2022–2025 · strength 0.50
  17. Joseph Tintelnot · 3 shared papers, 2023–2025 · strength 0.43
  18. Leonie Konczalla · 3 shared papers, 2022–2025 · strength 0.43
  19. Cenap Güngör · 3 shared papers, 2022–2025 · strength 0.43
  20. Fritz Klein · 7 shared papers, 2013–2018 · strength 0.42
  21. Stefan Hubert Boeck · 3 shared papers, 2022–2025 · strength 0.40
  22. Sabrina Sulzer · 1 shared paper, 2025 · strength 0.37
  23. Anna Maxi Wandmacher · 1 shared paper, 2025 · strength 0.37
  24. Timm Denecke · 5 shared papers, 2015–2018 · strength 0.31
  25. Danmei Zhang · 2 shared papers, 2023–2025 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.